Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quoin Pharmaceuticals Ltd. (QNRX) filings document a State of Israel registrant whose Nasdaq-listed American Depositary Shares each represent 35 ordinary shares. Recent 8-K reports record quarterly and annual financial results, Regulation FD disclosures and material events tied to the company's rare-disease drug-development programs.
The filing record includes disclosures about QRX003 regulatory designations for Netherton Syndrome, QRX009 topical rapamycin delivery technologies, capital-structure matters and board compensation arrangements. These reports also identify the ADS and ordinary-share structure and exchange listing for QNRX securities.
Quoin Pharmaceuticals reports that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation to QRX003 lotion (4%) for treating Netherton Syndrome, a rare genetic skin disorder with no approved treatments.
The Japanese designation covers diseases affecting fewer than 50,000 patients and provides prioritized consultation, reduced fees, tax incentives, priority review, and up to 10 years of market exclusivity upon approval.
QRX003 already holds Orphan Drug, Pediatric Rare Disease, and Fast Track designations from the U.S. FDA and Orphan Drug status from the European Medicines Agency. The drug is in Phase 2 trials, with a pivotal Phase 3 study expected in the second half of 2026 and potential NDA filing in 2027.
Quoin Pharmaceuticals Ltd. Schedule 13G: a group led by Millennium affiliates and Israel A. Englander reports shared beneficial ownership of 3,850,385 ordinary shares, representing 5.5% of the class, per cover-page disclosures. The filers executed a Joint Filing Agreement dated June 1, 2026. The filing notes CUSIP 74907L409 and that each American Depositary Share represents thirty-five Ordinary Shares.
Quoin Pharmaceuticals Ltd. updates its resale prospectus supplement to reflect a substitution in the Selling Shareholders table and the transfer of warrants tied to ADSs. The registration covers 10,045,455 American Depositary Shares (ADSs) representing 351,590,925 ordinary shares.
The supplement substitutes SILV Fund Ltd. for Point72 Associates, LLC for a transferred block of warrants to purchase 909,090 ADSs; the prospectus remains otherwise unchanged. The ADSs trade on Nasdaq under the symbol QNRX.
Quoin Pharmaceuticals, Ltd. Schedule 13G/A amendment reports beneficial ownership positions held or controlled by ADAR1-related entities and an individual, tied to American Depositary Shares (each representing 35 Ordinary Shares).
The filing states shared dispositive power of 102,846 and 102,883 Depositary Shares for named filers and cites 1,961,206 Depositary Shares outstanding as of March 31, 2026.
Quoin Pharmaceuticals, Ltd. ownership disclosure: Stonepine-affiliated reporting persons state beneficial ownership of 7,594,166 Ordinary Shares, representing 9.99% of the class. The filing explains holdings via American Depositary Shares (ADSs): 53,460 ADSs, pre-funded warrants for 81,212 ADSs, and ordinary warrants for 484,848 ADSs, with a 9.99% beneficial ownership limitation on the warrants. The percentage is calculated using 70,294,615 Ordinary Shares (represented by 2,008,417 ADSs) outstanding as of May 5, 2026, plus 1,400,000 Ordinary Shares represented by 40,000 ADSs issued on exercise after December 5, 2025.
The filing lists shared voting and dispositive power of 7,594,166 shares across Stonepine entities and Jon M. Plexico, and notes the Partnership holds ADSs for its investors. Signatures are dated 05/15/2026.
Woodline Partners LP reports beneficial ownership of 2,785,370 Ordinary Shares of Quoin Pharmaceuticals, Ltd., representing 4.4% of the class based on 63,126,930 Ordinary Shares outstanding as of March 23, 2026. The reporting statement notes the holdings are ADS-represented (one ADS = 35 Ordinary Shares) and is filed as an amendment to a Schedule 13G.
Quoin Pharmaceuticals Ltd. reported a wider first quarter 2026 net loss while highlighting major regulatory progress for its rare-disease pipeline. Net loss was about $5.0 million for the quarter ended March 31, 2026, compared with roughly $3.8 million a year earlier. Cash, cash equivalents and investments totaled approximately $14 million at March 31, 2026, which the company believes will fund operations into 2027.
Regulatory momentum centered on lead candidate QRX003 for Netherton Syndrome. The U.S. FDA granted Fast Track Designation, and a Type C meeting indicated a single Phase 3 study may support U.S. approval, potentially without a traditional placebo or vehicle control. Quoin filed for Breakthrough Medicine Designation in Saudi Arabia and submitted an Orphan Drug Designation application in Japan, where authorities confirmed QRX003 qualifies for both Orphan Drug and Fast Track review. Quoin aims to complete Phase 3 recruitment by the end of 2026 and potentially file an NDA in 2027.
The company also advanced its QRX009 topical rapamycin platform, planning investigator-led studies in Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, and targeting an additional U.S. IND filing in the third quarter of 2026.
Quoin Pharmaceuticals Ltd. reported a larger quarterly loss as it advances late-stage programs for rare skin diseases and faces a going concern warning. For the three months ended March 31, 2026, net loss widened to $4.99 million from $3.81 million a year earlier.
Research and development spending rose to $3.43 million, driven mainly by QRX003 clinical studies and early work on QRX009. General and administrative expenses were $1.70 million. Quoin ended the quarter with $3.12 million in cash and $10.92 million in U.S. Treasury investments, and an accumulated deficit of about $76.0 million.
Management concluded there is substantial doubt about the company’s ability to continue as a going concern for at least one year without new funding. The company continues pivotal preparations for QRX003 in Netherton Syndrome and development of QRX009, while holding nine commercial license and supply agreements that have not yet generated revenue.
Aberdeen Group plc reports beneficial ownership of 75,000 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd., representing 4.16% of the ADS class. Each ADS represents 35 ordinary shares.
The filing lists Aberdeen Group plc as the parent, with abrdn Inc. holding shared voting and dispositive power over the 75,000 ADS on behalf of underlying clients. Signatures are dated 04/29/2026.
Quoin Pharmaceuticals, Ltd. reported a Form 4 filing by Stonepine Capital Management, LLC, identified as a ten percent owner of QNRX. The summarized data shows no reported purchases, sales, exercises, gifts, or other share transactions in this filing.